Evaluation of inner retinal function assessed with a novel handheld instrument (RETeval) using flicker electroretinography after anti-VEGF treatment in patients with diabetic macular oedema

Détails

Ressource 1Télécharger: Mémoire no 5578 Mme Abdulghfor.pdf (552.33 [Ko])
Etat: Public
Version: Après imprimatur
Licence: Non spécifiée
ID Serval
serval:BIB_0F0C673CE262
Type
Mémoire
Sous-type
(Mémoire de) maîtrise (master)
Collection
Publications
Institution
Titre
Evaluation of inner retinal function assessed with a novel handheld instrument (RETeval) using flicker electroretinography after anti-VEGF treatment in patients with diabetic macular oedema
Auteur(s)
ABDULGHAFOR M.
Directeur(s)
WOLFENSBERGER T.
Codirecteur(s)
KONSTANTINIDIS L.
Détails de l'institution
Université de Lausanne, Faculté de biologie et médecine
Statut éditorial
Acceptée
Date de publication
2018
Langue
anglais
Nombre de pages
22
Résumé
Background
Electroretinographic studies have suggested that anti-VEGF treatment apart from its positive
impact on the diabetic macular oedema may have a more generalised impact on the entire retinal
function.
A portable, handheld, flash and flicker electro retinography (ERG) recording system has recently
been developed (RETeval™ LKC Technologies, Gaithersburg, MD) that makes it possible to
record ERGs more rapidly and less invasively than the conventional ERG systems.
We evaluate ERG measurements by the RETeval device before and after treatment with intravitreal
anti-VEGF injections in eyes with diabetic macular oedema associated with mild nonproliferative
diabetic retinopathy.
Methods
Prospective pilot study of 7 eyes of 5 patients with type II diabetes treated for macular edema by
intravitreal ranibizumab injections in Jules Gonin University Eye Hospital in Lausanne,
Switzerland. ERGs were recorded with the RETeval system before treatment and 1 month after
the 3rd injection. Measurements included responses to photoptic flicker and ERG recording
according to various protocols including photopic negative response (PhNR), ERGs recorded by
sinusoidal light stimulus and the RETeval specific diabetic retinopathy Assessment Protocol.
Additionally, fluorescein angiography was performed on each patient before and after treatment.
Results
All patients demonstrated significant improvement of visual acuity and resolution of macular
oedema after treatment. We found no significant differences of the amplitudes and implicit times
of ERGs after intravitreal injection of anti-VEGF with most of the protocols applied bar ERGs
recorded by sinusoidal light stimulus. The mean implicit time of the flicker ERGs recorded by
sinusoidal light stimulus was shortened significantly from 30.2 msec (SD: 0.6) at baseline to a
mean of 29 msec (SD:0.76,) after the last intravitreal injection (p< 0.05; paired t-test).
Additionally, the RETeval specific diabetic retinopathy Assessment Protocol designed to aid in the
detection of vision threatening diabetic retinopathy including clinically significant macular
oedema, could detect improvement in 71% of our cases.
Conclusion
In the present study we found no significant difference of the amplitudes and implicit times by
most protocols applied bar shortening of the implicit times after ranibizumab treatment using a
sinusoidal light stimulus. It is believed that sinusoidal stimulus is sensitive to inner-retinal function
though its significance is not yet clearly elucidated. Additionally, the RETeval specific DR
Assessment Protocol could detect improvement in the majority of our cases. The RETeval device
offers a novel, quick and easily accessible method of objective electroretinographic measurements
though the significance of its clinical role warrants further studies.
Mots-clé
Diabetic retinopathy, Diabetic macular oedema, Ranibizumab, Flicker electroretinogram, RETeval
Création de la notice
03/09/2019 8:54
Dernière modification de la notice
08/09/2020 6:08
Données d'usage